型号:_Monoamine Oxidase
产品价格:电议      采购度:1870      原产地:中国大陆
发布时间:2020/7/14 19:57:51 所属地区:上海 上海市
简要描述:
PXS-5153A monohydrochloride 是一种有效的、选择性的、具有口服活性和快速起效的赖氨酰氧化酶 2/3 (LOXL2/LOXL3) 的双抑制剂,对几乎所有哺乳动物LOXL2的IC50 均IC50 为63 nM。PXS-5153A monohydrochloride 可减少交联,改善纤维化。
标签:pxs5153a
产品详情
MCE 的所有产品仅用作科学研究,我们不为任何个人用途提供产品和服务。
MCE 站:PXS-5153A monohydrochloride
产品活性:PXS-5153A monohydrochloride 是一种有效的、选择性的、具有口服活性和快速起效的赖氨酰氧化酶 2/3 (LOXL2/LOXL3) 的双抑制剂,对几乎所有哺乳动物LOXL2的IC50 均< 40 nM,对人类LOXL3 的IC50 为63 nM。PXS-5153A monohydrochloride 可减少交联,改善纤维化。
研究领域:Neuronal Signaling
作用靶点:Monoamine Oxidase
In Vitro: PXS-5153A exhibits an IC50 of <40 nM for LOXL2 across all mammalian species tested. PXS-5153A also inhibits human LOXL3 with an IC50 value of 63 nM. PXS-5153A is >40-fold selective for LOXL2 over both LOX and LOXL1 and >700-fold selective over other related amine oxidases. PXS-5153A is a fast acting inhibitor, with enzymatic activity almost entirely blocked within 15 minutes .
In Vivo: As expected, rhLOXL2 dose-dependently induce oxidation of collagen with PXS-5153A dose-dependently impeding collagen oxidation. Therapeutic treatment of PXS-5153A substantially reduces immature crosslink formation compared with the CCl4 treated animals. Mature crosslink formation is also reduced by PXS-5153A treatment. All groups with therapeutic treatment of PXS-5153A show a significant reduction in DHLNL formation compared to the CCl4 treated animals. Treatment with PXS-5153A causes a significantly reduction in HYP compared to the CCl4 group. In addition, the amount of fibrillar collagen is markedly augmented by disease as seen by the 2.2-fold increase in percentage coverage area by Picrosirius red staining, which is reduced by PXS-5153A.
相关产品:Reprogramming Compound Library | Orally Active Compound Library | Neuronal Signaling Compound Library | Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | Phenelzine sulfate | GSK-LSD1 dihydrochloride | Tranylcypromine hemisulfate | Rosmarinic acid | Clorgyline hydrochloride | Methylene Blue | PAT-1251 | Pargyline hydrochloride | Rasagiline mesylate | Paeonol | (2-Chloropyridin-4-yl)methanamine hydrochloride | Mofegiline hydrochloride | Safinamide | Moclobemide | J-147 | Minaprine dihydrochloride | Nialamide | OG-L002 | Ro 41-1049 hydrochloride | CCT365623 hydrochloride | Iproniazid phosphate | Isocarboxazid | (S)-Rasagiline | Desmethoxyyangonin | Lazabemide | PXS-5153A | Toloxatone | Vafidemstat | Brofaromine
品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物;
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果;
• 专业团队跟踪*新的制药及生命科学研究进展,为您提供全球*新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。
更新时间:2024/1/2 10:11:33
留言咨询
温馨提示
1.遵守中华人民共和国有关法律、法规,尊重网上道德,承担一切因您的行为而直接或间接引起的法律责任。
2.请您真实的反映产品的情况,不要捏造、诬蔑、造谣。如对产品有任何疑问,也可以留言咨询。
3.未经本站同意,任何人不得利用本留言簿发布个人或团体的具有广告性质的信息或类似言论。
相关新闻
相关产品